A systematic review of ketamine for the management of vaso-occlusive pain in sickle cell disease
Emily M. Harris
Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts
Search for more papers by this authorEmily Vilk
Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Search for more papers by this authorMatthew M. Heeney
Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Search for more papers by this authorJean Solodiuk
Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts
Search for more papers by this authorChristine Greco
Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts
Search for more papers by this authorCorresponding Author
Natasha M. Archer
Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Correspondence
Natasha M. Archer, Pediatric Hematology/Oncology Dana-Farber/Boston Children's Cancer and Blood Disorders Center, 300 Longwood Avenue, Boston, MA 02215.
Email:[email protected]
Search for more papers by this authorEmily M. Harris
Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts
Search for more papers by this authorEmily Vilk
Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Search for more papers by this authorMatthew M. Heeney
Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Search for more papers by this authorJean Solodiuk
Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts
Search for more papers by this authorChristine Greco
Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, Massachusetts
Search for more papers by this authorCorresponding Author
Natasha M. Archer
Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts
Correspondence
Natasha M. Archer, Pediatric Hematology/Oncology Dana-Farber/Boston Children's Cancer and Blood Disorders Center, 300 Longwood Avenue, Boston, MA 02215.
Email:[email protected]
Search for more papers by this authorAbstract
Vaso-occlusive episodes (VOEs) are a common complication of sickle cell disease (SCD) and a significant cause of morbidity. Managing VOE pain can be difficult and complex. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been used to manage VOE pain. This systematic literature review synthesizes research published from 2010 to 2020 on the use of ketamine infusion to decrease VOE pain. The review demonstrates that ketamine, a safe and effective treatment for VOE pain, could be considered more widely. However, the significant variability among published clinical studies with regard to dosing, timing of initiation, duration of infusion, and timing of discontinuation highlights the need for standardized ketamine infusion protocols for the management of VOE pain. We conclude with a brief discussion of key components of a potential standardized protocol supported by the literature reviewed as well as areas for future investigation.
REFERENCES
- 1Gaston MH. Sickle cell disease: an overview. Semin Roentgenol. 1987; 22: 150-159.
- 2Hagedorn JM, Monico EC. Ketamine infusion for pain control in acute pediatric sickle cell painful crises. Pediatr Emer Care. 2019; 35: 78-79.
- 3Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. N Engl J Med. 1991; 325: 11-16.
- 4Ballas SK. Sickle cell disease: clinical management. Baillieres Clin Haematol. 1998; 11: 185-214.
- 5Steiner CA, Miller JL. Sickle cell disease patients in U.S. hospitals, 2004: statistical brief #21. Healthcare Cost and Utilization Project Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research; 2006.
- 6Darbari DS, Ballas SK, Clauw DJ. Thinking beyond sickling to better understand pain in sickle cell disease. Eur J Haematol. 2014; 93: 89-95.
- 7Solodiuk JC, Brighton H, McHale J, et al. Documented electronic medical record-based pain intensity scores at a tertiary pediatric medical center: a cohort analysis. J Pain Symptom Manage. 2014; 48(5): 924-933.
- 8Dunlop RJ, Bennett KCLB. Pain management for sickle cell disease. The Cochrane Collaboration. 2005; 2:CD003350.
- 9Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012; 120: 3647-3456.
- 10Dampier C, Palermo TM, Darbari DS, Hassell K, Smith W, Zempsky W. AAPT diagnostic criteria for chronic sickle cell disease pain. J Pain. 2017; 18(5): 490-498.
- 11Ballas SK. How I treat acute and persistent sickle cell pain. Mediterr J Hematol Infect Dis. 2020; 12(1):e2020064.
- 12Bell RF, Kalso EA. Ketamine for pain management. Pain Rep. 2018; 3(5):e674.
- 13Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018; 43(5): 521-546.
- 14Mikkelsen S, Ilkjaer S, Brennum J, Borgbjerg FM, Dahl JB. The effect of naloxone on ketamine-induced effects on hyperalgesia and ketamine-induced side effects in humans. Anesthesiology. 1999; 90(6): 1539-1545.
- 15Sarton E, Teppema LJ, Olievier C, et al. The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesthesia Analg. 2001; 93(6): 1495-1500.
- 16Dix P, Martindale S, Stoddart PA. Double blind randomized placebo-controlled trial of the effect of ketamine on post-operative morphine consumption in children following appendectomy. Paediatr Anaesth. 2003; 13: 422-426.
- 17Tsui BCH, Wagner A, Mahood J, et al. Adjunct continuous intravenous ketamine infusion for postoperative pain relief following posterior spinal instrumentation for correction of scoliosis: a case report. Paediatr Anaesth. 2007; 17: 383-386.
- 18Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M. Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain. 1994; 56: 51-57.
- 19Max MB, Byas-Smith M, Gracely RH, Bennett GJ. Intravenous infusion of the NMDA antagonist, ketamine, in chronic posttraumatic pain with allodynia; a double-blind comparison to alrentanil and placebo. Clin Neuropharmacol. 1995; 18: 360-368.
- 20Correll GE, Maleki J, Gracely EJ, Muir JJ, Harbut RE. Subanesthetic ketamine infusion therapy: a retrospective analysis of a novel approach to complex regional pain syndrome. Pain Med. 2004; 5(3): 263-275.
- 21Fisher K, Hagen NA. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. J Pain Symptom Manage. 1999; 18: 61-66.
- 22Tsui BCH, Davies D, Desai S, Malherbe S. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J Pedaitr Haematol Oncol. 2004; 26(10): 678-680.
- 23Klepstad P, Borchgrevink P, Hval B, Flatt S, Kaasa S. Long-term treatment with ketamine in a 12-year-old girl with severe neuropathic pain caused by a cervical spinal tumor. J Pediatr Hematol Oncol. 2001; 23: 616-619.
- 24Finkel JC, Pestieau SR, Quexado ZMN. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain. 2007; 8: 515-521.
- 25Sheehy KA, Lippold C, Rice AL, Nobrega R, Finkel JC, Quezado ZMN. Subanesthetic ketamine for pain management in hospitalized children, adolescents, and young adults: a single-center cohort study. J Pain Res. 2017; 10: 787-795.
- 26Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018; 43(5): 456-466.
- 27Zempsky WT, Loiselle KA, Corsi JM, Hagstrom JN. Use of low dose ketamine infusion for pediatric patients with sickle cell disease-related pain: a case series. Clin J Pain. 2010; 26: 163-167.
- 28Meals CG, Mullican BD, Shaffer CM, Dangerfield PF, Ramirez RP. Ketamine infusion for sickle cell crisis pain in an adult. J Pain Symptom Manage. 2011; 42(3): E7-E9.
- 29Jennings CA, Bobb BT, Noreika DM, Coyne PJ. Oral ketamine for sickle cell crisis pain refractory to opioids. J Pain Pall Care Pharm. 2013; 27: 150-154.
- 30Uprety D, Baber A, Foy M. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of the literature. Ann Hematol. 2014; 93: 769-771.
- 31Kerr C, Holahan T, Milch R. The use of ketamine in severe cases of refractory pain syndromes in the palliative care setting: a case series. J Palliative Medicine. 2011; 14(9): 1074-1077.
- 32Gimovsky AC, Fritton K, Viscusi E, Roman A. Evaluating the use of ketamine for pain control with sickle cell crisis in pregnancy: a report of 2 cases. A & A Practice. 2018; 10: 20-22.
- 33Palm N, Floroff C, Hassig TB, Boylan A, Kanter J. Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: a case series. J Pain Pall Care Pharm. 2018; 32(1): 20-26.
- 34Lubega FA, DeSilva MS, Munube D, et al. Low dose ketamine versus morphine for acute severe vaso occlusive pain in children: a randomized controlled trial. Scand J Pain. 2018; 18(1): 19-27.
- 35Nobrega R, Sheehy KA, Lippold C, Rice AL, Finkel JC, Quezado ZMN. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease. Pediatr Res. 2018; 83(2): 445-454.
- 36Skolnick P. The opioid epidemic: crisis and solutions. Annu Rev Pharmacol Toxicol. 2018; 58: 143-159.
- 37Tawfic QA, Faris AS, Kausalya R. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. J Pain Symptom Manage. 2014; 47: 334-340.
- 38Neri CM, Pestieau SR, Young H, Elmi A, Finkel JC, Darbari DS. Low-dose ketamine for children and adolescents with acute sickle cell disease related pain: a single center experience. J Anesth Clin Res. 2013; 5(3): 684-689.
- 39Kator S, Correll D, Ou J, Levinson R, Noronha GN, Adams CD. Assessment of low-dose i.v. ketamine infusions for adjunctive analgesia. Am J Health Syst Pharm. 2016; 73(5): S22-S29.
- 40Sheehy KA, Muller EA, Lippold C, Nouraine M, Finkel JC, Quezado ZMN. Subanesthetic ketamine infusions for the treatment of children and adolescents with chronic pain: a longitudinal study. BMC Pediatrics. 2015; 15: 198.
- 41Puri L, Morgan KJ, Anghelescu DL. Ketamine and lidocaine infusions decrease opioid consumption during vaso-occlusive crisis in adolescents with sickle cell disease. Curr Opin Support Palliat Care. 2019; 13: 402-407.
- 42Ahern TL, Herring AA, Miller S, Frazee BW. Low-dose ketamine infusion for emergency department patients with severe pain. Pain Med. 2015; 16(7): 1402-1409.
- 43Motov S, Drapkin J, Likourezos A, Doros J, Monfort R, Marshall J. Sub-dissociative dose ketamine administration for managing pain in the emergency department. World J Emerg Med. 2018; 9(4): 249-255.
- 44Motov S, Drapkin J, Likourezos A, et al. Continuous intravenous sub-dissociative dose ketamine infusion for managing pain in the emergency department. West J Emerg Med. 2018; 19(3): 559-566.
- 45Neri CM, Pestieau SR, Darbari DS. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease. Paediatr Anaesth. 2013; 23: 684-689.
- 46Sanacora G, Frye MA, McDonald W, et al. American Psychiatric Association (APA) Council of research task force on novel biomarkers and treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017; 74(4): 399-405.
- 47Kim M, Cho S, Lee JH, The effects of long-term ketamine treatment on cognitive function in complex regional pain syndrome: a preliminary study. 2016; 17(8): 1447-1451.
